Pharmorage

Pharmorage is an Australian biotechnology company and wholly owned subsidiary of Noxopharm focused on anti-inflammatory oligonucleotide therapeutics and technologies that improve the safety profile of mRNA vaccines and RNA therapeutics. The company was formed through a strategic collaboration with Hudson Institute of Medical Research, with additional scientific links to the Australian National University. Its programs are built around ultra-short oligonucleotides designed to modulate innate immune sensors that drive aberrant inflammation. Pharmorage is pursuing preclinical opportunities in autoimmune and inflammatory diseases, including lupus, psoriasis, type 1 diabetes, rheumatoid arthritis, and multiple sclerosis, while also developing the SOF-VAC program for mRNA vaccine and therapeutic enhancement. The company appears to operate primarily as a research-stage subsidiary supporting Noxopharm’s broader Sofra platform.